ERAS · Company research
Erasca, Inc. Common Stock (ERAS): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
21records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Erasca, Inc: The Discount RevMed? (NASDAQ:ERAS) - Seeking Alpha | Erasca, Inc: The Discount RevMed? (NASDAQ:ERAS) Seeking Alpha | View source ↗ | Seeking Alpha | Oct 15, 2026 | neutral | 0 | 0.6 |
| An 8,333-share Erasca (ERAS) sale is proposed by Erasca Foundation, with shares valued at $122K. - Stock Titan | An 8,333-share Erasca (ERAS) sale is proposed by Erasca Foundation, with shares valued at $122K. Stock Titan | View source ↗ | Stock Titan | Oct 15, 2026 | neutral | 0 | 0.6 |
| ERAS Stock Slumps Nearly 40% After-Hours: Fine Print In 'Positive' Cancer Trial Reveals Treatment-Related Death - Stocktwits | ERAS Stock Slumps Nearly 40% After-Hours: Fine Print In 'Positive' Cancer Trial Reveals Treatment-Related Death Stocktwits | View source ↗ | Stocktwits | Oct 14, 2026 | neutral | 0 | 0.6 |
| ERAS Stock Technical Analysis - Pluang | ERAS Stock Technical Analysis Pluang | View source ↗ | Pluang | Oct 10, 2026 | neutral | 0 | 0.6 |
| ERAS Stock Slumps Against RVMD Rally — Analyst Stays Bullish - Stocktwits | ERAS Stock Slumps Against RVMD Rally — Analyst Stays Bullish Stocktwits | View source ↗ | Stocktwits | Oct 9, 2026 | neutral | 0 | 0.6 |
| VKTX Stock Outpaces LLY, ALT Ahead Of Earnings – Retail Eyes Breakout Ahead - Stocktwits | VKTX Stock Outpaces LLY, ALT Ahead Of Earnings – Retail Eyes Breakout Ahead Stocktwits | View source ↗ | Stocktwits | Oct 8, 2026 | neutral | 0 | 0.6 |
| Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); Erasca, Inc. (NASDAQ: ERAS); and New Era Energy & Digital, Inc. (NASDAQ: NUAI): Grabar Law Office is Investigating Claims on Your Behalf | Grabar Law Office is investigating securities fraud and fiduciary duty breach claims against four companies: Aardvark Therapeutics for allegedly misrepresenting the safety profile of its drug candidate ARD-101 before a clinical hold was placed; Coastal Financial Corporation for failing to disclose deterioration in its CCBX partner loan portfolio and credit losses; Erasca, Inc. for making misleading statements about its ERAS-0015 therapy and improper comparisons to competitors; and New Era Energy & Digital for overstating progress on its data center project and allegedly engaging in fraudulent oil-and-gas schemes. | View source ↗ | GlobeNewswire Inc. | Oct 8, 2026 | bearish | -1 | 1 |
| Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); Erasca, Inc. (NASDAQ: ERAS); and New Era Energy & Digital, Inc. (NASDAQ: NUAI): Grabar Law Office is Investigating Claims on Your Behalf | Grabar Law Office is investigating securities fraud and fiduciary duty breach claims against four companies: Aardvark Therapeutics for allegedly misrepresenting the safety profile of its drug candidate ARD-101 before a clinical hold was placed; Coastal Financial Corporation for failing to disclose deterioration in its CCBX partner loan portfolio and credit losses; Erasca, Inc. for making misleading statements about its ERAS-0015 therapy and improper comparisons to competitors; and New Era Energy & Digital for overstating progress on its data center project and allegedly engaging in fraudulent oil-and-gas schemes. | View source ↗ | GlobeNewswire Inc. | Oct 8, 2026 | bearish | -1 | 1 |
| Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); Erasca, Inc. (NASDAQ: ERAS); and New Era Energy & Digital, Inc. (NASDAQ: NUAI): Grabar Law Office is Investigating Claims on Your Behalf | Grabar Law Office is investigating securities fraud and fiduciary duty breach claims against four companies: Aardvark Therapeutics for allegedly misrepresenting the safety profile of its drug candidate ARD-101 before a clinical hold was placed; Coastal Financial Corporation for failing to disclose deterioration in its CCBX partner loan portfolio and credit losses; Erasca, Inc. for making misleading statements about its ERAS-0015 therapy and improper comparisons to competitors; and New Era Energy & Digital for overstating progress on its data center project and allegedly engaging in fraudulent oil-and-gas schemes. | View source ↗ | GlobeNewswire Inc. | Oct 8, 2026 | bearish | -1 | 1 |
| FDA Grants Fast Track Designation to ERAS-0015 for Pancreatic Adenocarcinoma - CancerNetwork | FDA Grants Fast Track Designation to ERAS-0015 for Pancreatic Adenocarcinoma CancerNetwork | View source ↗ | CancerNetwork | Aug 25, 2026 | neutral | 0 | 0.6 |
| Erasca reports 57% preliminary response in patients with later-line KRAS G12X pancreatic cancer - Stock Titan | Erasca reports 57% preliminary response in patients with later-line KRAS G12X pancreatic cancer Stock Titan | View source ↗ | Stock Titan | Aug 24, 2026 | neutral | 0 | 0.6 |
| Erasca (ERAS) Stock Looks Overvalued On Price But Strong On Returns - Yahoo Finance | Erasca (ERAS) Stock Looks Overvalued On Price But Strong On Returns Yahoo Finance | View source ↗ | Yahoo Finance | Jul 15, 2026 | neutral | 0 | 0.6 |
| Is Erasca (ERAS) Stock Trading At A Premium After New Trial Data? - Simply Wall Street | Is Erasca (ERAS) Stock Trading At A Premium After New Trial Data? Simply Wall Street | View source ↗ | Simply Wall Street | Jul 15, 2026 | neutral | 0 | 0.6 |
| Why Erasca (ERAS) Stock Is Up Today - Quiver Quantitative | Why Erasca (ERAS) Stock Is Up Today Quiver Quantitative | View source ↗ | Quiver Quantitative | Jul 14, 2026 | neutral | 0 | 0.6 |
| Lost Money on Erasca, Inc. (ERAS)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky - PR Newswire | Lost Money on Erasca, Inc. (ERAS)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky PR Newswire | View source ↗ | PR Newswire | Jul 8, 2026 | neutral | 0 | 0.6 |
| Here is Why Erasca (ERAS) is One of the Best Growth Stocks Under $20 - Yahoo Finance | Here is Why Erasca (ERAS) is One of the Best Growth Stocks Under $20 Yahoo Finance | View source ↗ | Yahoo Finance | Jun 3, 2026 | neutral | 0 | 0.6 |
| $ERAS stock is up 12% today. Here's what we see in our data. | ERAS Stock News - Quiver Quantitative | $ERAS stock is up 12% today. Here's what we see in our data. | ERAS Stock News Quiver Quantitative | View source ↗ | Quiver Quantitative | Jun 1, 2026 | neutral | 0 | 0.6 |
| JPMorgan Recommends Buying Erasca (ERAS) Stock at Current Levels - Yahoo Finance | JPMorgan Recommends Buying Erasca (ERAS) Stock at Current Levels Yahoo Finance | View source ↗ | Yahoo Finance | May 10, 2026 | neutral | 0 | 0.6 |
| StockWatch: Patient Death, Rival's Patent Challenge Sink Erasca Shares - Genetic Engineering and Biotechnology News | StockWatch: Patient Death, Rival's Patent Challenge Sink Erasca Shares Genetic Engineering and Biotechnology News | View source ↗ | Genetic Engineering and Biotechnology News | May 3, 2026 | neutral | 0 | 0.6 |
| Erasca hits ‘home run’ with cancer data as analyst suggests stock drop prompted by patient death - Fierce Biotech | Erasca hits ‘home run’ with cancer data as analyst suggests stock drop prompted by patient death Fierce Biotech | View source ↗ | Fierce Biotech | Apr 28, 2026 | neutral | 0 | 0.6 |
| Erasca shares rise as company narrows timing for key ERAS-0015 Phase 1 data readout | ERAS Stock News - Quiver Quantitative | Erasca shares rise as company narrows timing for key ERAS-0015 Phase 1 data readout | ERAS Stock News Quiver Quantitative | View source ↗ | Quiver Quantitative | Apr 21, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.